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ABSTRACT
Introduction Chronic active antibody-mediated rejection (cAMR) is a major determinant of late 
allograft failure. Rituximab/immunoglobulins (IVIg) + plasma exchange (PLEX) showed 
controversial results in cAMR treatment. Tocilizumab (TCZ), a humanized anti-interleukin 6 
receptor antibody, has been recently used as rescue therapy in patients non-responsive to 
rituximab/IVIg/PLEX with favorable outcomes. Whether TCZ acts “per se” or requires a priming 
effect from previous treatments is currently unknown.
Methods 15 patients with cAMR were treated with TCZ as a first-line therapy and followed for a 
median time of 20.7 months.
Results Despite the majority of patients experiencing advanced transplant glomerulopathy (TG) at 
diagnosis (60% with cg3), glomerular filtration rate and proteinuria stabilized during the follow-
up, with a significant reduction in donor-specific antibodies. Protocol biopsies after 6 months 
demonstrated significant amelioration of microvascular inflammation and no TG, C4d deposition 
or IF/TA progression. Gene-expression and immunofluorescence analysis showed upregulation of 
three genes (TJP-1, AKR1C3 and CASK) involved in podocyte, mesangial and tubular restoration.
Conclusion TCZ adopted as a first-line approach in cAMR was associated with early serological 
and histological improvements and functional stabilization even in advanced TG, suggesting a role 
for the use of TCZ alone with the avoidance of unnecessary previous immunosuppressants.
KEY WORDS: Tocilizumab; Chronic antibody-mediated rejection; Transplant glomerulopathy; 
Kidney transplantation; donor specific antibodies; anti-HLA antibody; angiotensin II type I-
receptor antibody
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ABBREVIATIONS
AEs/SAEs adverse events/severe adverse events
AKR1C3 aldo-keto reductase family 1 member C3
AT1R-Abs anti–angiotensin type 1 receptor antibodies
cAMR chronic active antibody-mediated rejection
CASK calcium/calmodulin dependent serine protein kinase
CNI calcineurin inhibitors
CTR healthy controls
DSAs/iDSAs donor-specific antibodies/immunodominant donor-specific antibodies
eGFR estimated glomerular filtration rate
ENDATs endothelial transcripts

















TJP-1 tight junction protein-1
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INTRODUCTION
Long-term graft survival remains a major challenge in kidney transplantation. A leading cause of 
late allograft failure is chronic active antibody mediated rejection (cAMR), mostly due to anti-
HLA donor-specific antibodies (DSA)1. Different approaches have been adopted to reduce the 
production and the detrimental effect of DSAs. Initial studies showed a benefit from the use of the 
anti-CD20 monoclonal antibody rituximab in combination with high-dose intravenous 
immunoglobulins (IVIg)2–4, but recent experiences, including our case series, have not confirmed 
these results, even with the addition of plasmapheresis (PLEX)5–7. More recently, a multicenter 
randomized trial comparing PLEX/IVIg with or without rituximab did not find any benefit of 
rituximab on cAMR outcomes8. Other therapies such as the anti-proteasome inhibitor bortezomib9 
or anti-C5b-9 eculizumab10 were studied in randomized trials without effect.
In 2017 Choi et al reported favorable effects in 36 patients with cAMR unresponsive to 
rituximab/PLEX/IVIg after 2 years of treatment with tocilizumab (TCZ), a humanized monoclonal 
antibody against the interleukin 6 (IL-6) receptor11. In this study DSA levels declined with renal 
function stabilization, improvement in microvascular inflammation (g + ptc and C4d scores) and 
no progression of transplant glomerulopathy (cg score) at a 1-year protocol biopsy. 
It is currently unknown whether the effects of TCZ as a rescue therapy after rituximab 
were primed by B-cell depletion before cytokine interference. Indeed, the cumulative effect of 
multiple lines of therapy may potentially impact safety, particularly considering chronic treatments 
such as TCZ12,13. In addition, the continuous change in the demography of recipients toward an 
older age and a frail profile14–16 may considerably influence the risk/benefit balance of increasing 
long-term immunosuppressive load. In this context avoidance of unnecessary treatments is 
mandatory.
In the present study we report our experience in 15 cAMR patients with severe transplant 
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MATERIALS AND METHODS
Patients and study design
We performed a single‐center, open‐label, non-sponsored case study at the Division of 
Nephrology, Dialysis and Transplantation of Città della Salute e della Scienza di Torino, 
University Hospital. The study was approved by both the internal Ethical and Pharmaceutical 
Committees. TCZ treatment was funded by the Italian Medicines Agency - Ministry of Health 
(AIFA) through the AIFA 5% fund.
Between 2016 and 2018, 15 patients with cAMR according to Banff criteria17 and without 
any previous therapy for cAMR, including rituximab, IVIg, PLEX, high dose steroids, bortezomib, 
anti-thymoglobulin or complement blockers, were treated with TCZ. One patient was treated with 
pulse steroids/IVIg/rituximab/PLEX as part of a desensitization protocol for an ABO-incompatible 
donor 6 years prior to the cAMR diagnosis and subsequent TCZ treatment, and one patient (6.7%) 
had a previous acute AMR episode treated with pulse steroids and PLEX/IVIg 30 months before 
cAMR. All biopsies were reviewed by a single pathologist with 20-years of experience in kidney 
allograft histology. All patients gave written informed consent after description of the potential 
risks and benefits of TCZ. Before the initiation of TCZ, patients were tested for viral infections 
(HBV, HCV, HIV) and for exposure to tuberculosis using the purified protein derivative skin test 
or QuantiFERON-TB test. Negative chest x-ray, abdomen ultrasound scan and cardiological 
assessment were required before starting treatment.
TCZ was given at a dose of 8 mg/kg (maximum of 800 mg) after premedication with 
steroids, paracetamol and chlorphenamine in our Ambulatory Transplantation Department with 
constant monitoring during the 60 min infusion time. Doses were scheduled monthly, and TCZ 
was continuously maintained if no adverse events (AEs) were recorded.
After initiation of therapy, patients were closely monitored for renal function, proteinuria, 
graft and patient survival, DSA levels (anti-HLA and anti–angiotensin type 1 receptor antibodies 
[AT1R-Ab]) and AEs and severe AEs. In order to evaluate early histological changes, a protocol 
graft biopsy was performed approximately 6 months after TCZ initiation (median 7.7 months; 6.8-
8.6).
For immunosuppressive maintenance, all patients were treated with a calcineurin inhibitor 
(CNI)-based immunosuppressor (20.0% cyclosporine A, 80.0% tacrolimus) plus mycophenolate 
mofetil/mycophenolic acid (MMF/MPA, 46.7%); 10 patients (66.7%) were also on steroids at the 
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MMF/MPA and/or steroids (with contemporary suspension of mTOR inhibitor, if used) or 
switching from cyclosporine A to tacrolimus (TAC) in patients who were not already on 
TAC/MMF/steroids (12/15, 80.0%). In one patient with severe graft dysfunction, conversion to 
belatacept with maintenance of low-dose tacrolimus (target range 2-3 ng/mL) was performed 7.9 
months before TCZ initiation.
Serology
Sera were evaluated both at the time of the index biopsy and the 6-month protocol biopsy. All 
samples were tested using a Luminex platform and commercially available SAB kits (LABScreen, 
One Lambda Inc, Canoga Park, CA, USA) in order to identify HLA Class  I and II IgG DSA. The 
cut-off was set at the normalized mean fluorescence intensity (MFI) value of 1000. We also tested 
AT1R‐Ab IgG using a commercial enzyme‐linked immunosorbent assay (ELISA) kit (One 
Lambda Inc, Canoga Park, CA, USA). 
Gene expression analysis
In gene expression analysis we evaluated the baseline and 6-month protocol biopsy in 11 
transplanted patients with normal histology and similar clinical characteristics (control group). For 
each sample, total RNA was extracted from 3 pieces of 10 µm sections of Serra’s fluid-fixed, 
paraffin-embedded samples by PureLink FFPE Total RNA Isolation Kit (Invitrogen, Thermo 
Fisher Scientific) according to the manufacturer’s instructions. RNA concentration was assessed 
using a MySpec instrument (VWR), and cDNA was produced from 400 ng of total RNA using the 
Super Script IV VILO Master Mix with ezDNase enzyme (Invitrogen, Thermo Fisher Scientific).
In addition, the expression profile of a panel of 43 endothelial, mesangial and podocyte genes 
directly involved in antibody mediated rejection and/or glomerulonephritis [Supplementary Table 
1; references10,18–23] was also tested. Gene expression for each target gene and five endogenous 
controls was measured using a specific TaqMan® Gene Expression Assay (Thermo Fisher 
Scientific) spotted on a custom TaqMan® Array microfluidic card (Thermo Fisher Scientific). The 
samples were mixed with TaqMan® Fast Advanced Master Mix (Thermo Fisher Scientific), and 
TaqMan® Array microfluidic cards were prepared according to the manufacturer’s instructions 
and run using the QuantStudio 12K Flex Real-Time PCR System (Thermo Fisher Scientific). Each 
sample was run in duplicate. Retrotranscription negative controls (no retrotranscription enzyme) 
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microfluidic card. Both negative controls showed no amplification at Ct < 37. ExpressionSuite 
Software 1.0.3 (Thermo Fisher Scientific) was used to calculate relative quantification (RQ) 
values by the 2-ΔΔCt method. Values of Ct > 37 or Cq conf < 0.6 were excluded from analysis. 
18s and NPHS2 were set as endogenous controls for multiple endogenous control analysis. Data 
were normalized to the expression level of healthy controls (CTR).
Immunofluorescence assay
Serial separated sections of frozen tissue from pre- and post-treatment biopsies (available in 6 
patients) were fixed in cold acetone for 10 min, washed with 0.1% PBS-BSA, blocked with 1% 
PBS-BSA and subsequently incubated with mouse monoclonal IgG1 anti-human tight junction 
protein 1 (TJP1) FITC-conjugated (Thermo Fisher Scientific, Waltham, MA, USA) (5 µg/ml), 
rabbit polyclonal anti-aldo-keto reductase family 1 member C3 (AKR1C3) (Thermo Fisher 
Scientific, Waltham, MA, USA) (1:250), rabbit polyclonal anti-calcium/calmodulin dependent 
serine protein kinase (CASK) (Thermo Fisher Scientific, Waltham, MA, USA) (1:20) and a 
secondary fluorescein anti-rabbit antibody (goat anti-rabbit IgG Alexa Fluor® 594, Thermo Fisher 
Scientific, Waltham, MA, USA) (1:500) for 1h at room temperature. The sections were washed 
again, nuclear stained with Hoechst dye 33258 2.5 μg/mL (Sigma-Aldrich, St. Louis, MO, USA) 
mounted and observed under a confocal microscope (Leica SP5, Leica Microsystems, Mannheim, 
Germany). Digital images were processed using Fiji-ImageJ software23.
Statistical analysis
Statistical analysis was performed with SPSS (IBM SPSS Statistics, vers. 25.0.0). Continuous 
variables are presented as mean ± standard deviation or as median and interquartile range (IQR), 
according to their distribution. Normal distribution was analyzed using a Kolmogorov-Smirnov 
test. The differences between before and after observations were analyzed using a paired Student’s 
t-test or Wilcoxon test. Categorical variables are presented as fractions. Gene expression analysis 
was performed using GraphPad Prism 6.01 software on RQ values using a nonparametric Kruskal-
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RESULTS
Baseline characteristics
Table 1 shows the baseline characteristics of our population. Twelve out of 15 patients (80.0%) 
received a deceased-donor kidney transplant, and 3/15 (20.0%) received a kidney from an 
extended-criteria donor according to Crystal City criteria28. Two out of 15 (13.3%) were 
retransplants. Most patients were men (12/15, 80.0%) with a median age at the time of 
transplantation of 38.3 years (23.0-47.5). The median number of HLA mismatches was 4 (3-4.5). 
The median vPRA was 3.5% (0-83.75), with 3 patients displaying a total vPRA>80%. 
All patients had HLA-DSAs, mostly anti-class II and de novo (14/15, 93.3%). In patients with 
available sera, 11/13 (84.6%) also showed elevated levels of AT1R-Ab at the time of cAMR 
diagnosis.
cAMR was diagnosed by a for-cause biopsy at a median time of 5.9 years (4.6-14.0) after 
transplantation, and TCZ was started at a median time of 100 days (79-137.5) after the biopsy. At 
diagnosis most of the patients experienced both severe transplant glomerulopathy (median cg 
score 3, 2-3) and microvascular inflammation (g + ptc score 3, 2-4).
Functional, histological and serological modifications after TCZ
Patients were monitored for a median time of 20.7 months (18.0-27.8, max 38.1 months) from the 
first TCZ dose. Graft loss was observed in only one patient (6.7%), 30 months after diagnosis and 
25.3 months after initiation of TCZ treatment. Considering the entire population, both estimated 
glomerular filtration rate (eGFR) and 24-hour proteinuria showed stabilization at the 12 month 
follow up (Fig. 1A-B). eGFR declined by 10.5 ml/min/1.73m2 (median) in the 12 months before 
cAMR diagnosis compared to 4.4 ml/min/1.73m2 the first year after diagnosis. Median proteinuria 
at diagnosis and at the 12 month follow up were 1.1 and 1 g/day, respectively.
These results were combined with a significant reduction in microvascular inflammation (g 
+ ptc score 3, 2-4 pre-TCZ vs 2; 1-2.5 post-TCZ; p=0.014) and an absence of progression in 
chronicity scores (cg and IF/TA) or C4d deposition (Table 2, Fig. 2A-B). In two cases with 
relevant interstitial edema at the index biopsy we also observed a remarkable decrease in 
inflammation after TCZ treatment.
Figure 3A-B and Table 2 display the impact of TCZ on immunodominant anti-HLA-DSA 
(iDSA) levels in this population. iDSAs were defined as DSAs with highest MFI detected in 
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pre-TCZ and 18200, 12650-22150 post-TCZ; p = 0.002), with complete negativization in one 
patient. This trend was also confirmed for AT1R-Ab (Fig. 3C). After 6 months treatment with 
TCZ, median AT1R-Ab levels were significantly reduced (15.8, 12.5-16.6 U/mL pre-TCZ and 8.4, 
6.8-11.3 post-TCZ; p = 0.003) with negativization in six patients.
These results appear to be further confirmed in an additional cohort of 13 patients with TG 
currently in treatment with TCZ in our center, in which there was no graft failure in DSA positive 
(anti-HLA/AT1R‐Ab) subjects (data not shown).
Gene expression analysis and immunofluorescence assay pre- and post-TCZ
We compared baseline gene expression values at cAMR diagnosis to the control group and post-
TCZ protocol biopsies. We observed an upregulation of ENDATs in cAMR patients compared to 
the control group but no differences before and after treatment with TCZ, a finding that may 
reflect the short period of observation (Fig. 4A). On the other hand, we identified three other genes 
differentially expressed before and after treatment with TCZ in the panel of mesangial and 
podocyte-related genes (Figure 4B). TJP-1 and AKR1C3 showed a non-significant reduction at 
baseline compared to controls but were significantly upregulated after treatment with TCZ 
compared to baseline. CASK was significantly downregulated at baseline compared to the control 
group and was significantly upregulated after treatment.
These trends were confirmed by immunofluorescence assay, with an increase in mean 
intensity after treatment for TJP-1 (16.336 vs 27.367 AU) and AKR1C3 (5.785 vs 8.778 AU) (Fig. 
5A-D). CASK mean intensity was similar before and after treatment (8.021 vs 7.713 AU), 
although some patients showed a moderate increase (Fig. 5E-F).
Adverse events
During the follow-up, 5 patients (33.3%) experienced bacterial infections (4 in the urinary tract, 
and 1 in the lower respiratory tract) which were promptly resolved with medical therapy, and no 
hospitalization or cessation of TCZ therapy were needed. In one patient an encephalitis of 
undefined origin was observed three months after TCZ initiation. Although the event was not 
related to TCZ and all serological, virological (including JC, Toscana and West Nile viruses) and 
bacteriological tests on blood and cerebrospinal fluid were negative, the drug was temporarily 
suspended and restarted after complete clinical recovery. Two years later, the same patient 
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patients developed interstitial lung disease. In one patient adenovirus was detected on 
bronchoalveolar lavage, so TCZ was temporarily suspended and restarted after complete recovery. 
In the other patient microbiological tests were negative, and a causal relationship with TCZ was 
suspected, so the therapy was stopped completely. Four patients (26.7%) developed 
hypogammaglobulinemia (< 450 mg/dl) during TCZ therapy, and IVIg replacement was required 
in one of them. Three patients (20.0%) had asymptomatic mild alterations in liver enzymes, and 
one had an increase in pancreatic enzymes. In these cases, TCZ was maintained, and tests were 
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DISCUSSION
There are few treatment options for cAMR in the field of renal transplantation. Graft loss is 
predominantly related to this condition24,25, and improvement has been debatable after the 
adoption of commonly considered “standard-of-care” therapies (PLEX, IVIg, rituximab), but also 
with novel approaches (bortezomib, eculizumab)9,10,26. Adverse effects are not observed in 
desensitization protocols that adopt rituximab with IVIg27; however, rituximab treatment is also 
associated with higher risk of infectious complications that may be particularly insidious in 
immunosuppressed patients26,28–30, further bringing into question its use in cAMR based on its 
risk-benefit ratio.
The anti-IL-6 receptor antibody TCZ has been used as a rescue therapy for cAMR after 
failure of rituximab/IVIg with or without PLEX with favorable results in reducing alloantibodies, 
ameliorating rejection lesions and slowing renal function deterioration11,31. Extension of this case 
series and some preliminary reports from other groups support these findings32–35. However, the 
individual role of IL-6 pathway blockade in treating cAMR with TCZ following failure of 
rituximab treatment has not been identified. Even if those treatments were not concomitant, it is 
well known that even a single dose of rituximab may exert long-term impact in kidney 
transplanted patients36. On these bases, one can speculate that the observed effect of TCZ may 
require as “priming” a first-line treatment with rituximab. The depletion of mature B-cells may 
theoretically synergize with the interfering effect of TCZ in B-cell maturation and T-B cell 
interaction. On the other hand, in vitro studies have shown that rituximab may induce IL-6 
secretion by resting and activated B cells37, a notion that may partially explain the lack of DSA 
level reduction after rituximab8 but not after TCZ31.
Our study shows that TCZ as a first-line treatment is associated with functional, serological 
and histological effects mirroring those observed by Choi et al11. Additionally, in our study the 
stabilization of kidney function occurred in a cohort with similar mean eGFR at presentation (49.8 
± 13.4 vs 48.4 ± 34.6 mL/min) but a worse degree of TG (cg score 2.47 ± 0.74 vs 1.57 ± 1.03 and 
60% of index biopsies having a cg score of 3) and a higher rate of transplant from deceased 
donors, especially from extended criteria ones (20% vs 2.8%).
Redfield et al25 observed that graft survival in 123 patients with cAMR and high chronicity 
scores was strongly associated with early allograft loss (30% graft survival at 1 year, 20% at 2 
years) with a significant impact of higher cg score in graft failure. In the present study, with a 
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their graft, even with a high median cg score. Despite the obvious limitations of an observational 
study and a limited follow-up, the stability of renal function in our TCZ treated population is 
particularly striking, emphasizing the possible positive role of IL-6 blockade even in the presence 
of severe glomerular chronic lesions with reduced renal function.
In their recent sub-analysis, Shin et al showed that TCZ reduced total IgG and IgG1-3, and 
anti-HLA-total IgG and IgG3 levels, suggesting that it non-specifically suppresses Ig production 
in B cells, likely through inhibition of IL-6-mediated signaling to B cells and plasma cells31. In our 
study TCZ was similarly associated with a significant reduction in anti-HLA DSAs. However, it is 
well known that a relevant portion of patients with AMR may not exhibit anti-HLA antibodies, 
nevertheless developing rejection lesions via antibodies directed to other kidney antigens38,39. 
Lefaucheur et al40 recently showed that AMR patients with AT1R but not anti-HLA antibodies 
have a higher prevalence of hypertension, more vascular rejection with arterial inflammation, 
higher levels of ENDATs, and lack of complement deposition in allograft capillaries, suggesting 
that AT1R-Abs may identify kidney transplant recipients at high risk of allograft rejection and 
loss, independent of the HLA system. Despite these results, clinical effects (also in Lefaucheur et 
al40) have been shown only in a reduced percentage of positive AT1R patients, and cut-off values 
were still a matter of debate40–44. In our present work we showed that TCZ is also able to reduce 
AT1R-Ab levels, a finding that has not been previously reported to the best of our knowledge.
Analyzing histology, TCZ is associated with an early reduction in microvascular 
inflammation at the 6-month protocol biopsy, reflecting the results of Choi et al11 at a 1-year 
biopsy. Additionally, our results also showed the efficacy of IL-6 signaling interference in local 
inflammation that may potentially anticipate DSA reduction, in particular in the glomerular 
compartment, where local IL-6 may be produced not only by activated endothelial cells but also 
by mesangial cells which also express the IL-6 receptor45–47. We attempted to analyze these 
changes at the biopsy gene-expression level, and we observed upregulation of three podocyte and 
mesangial-related genes (TJP-1, AKR1C3 and CASK) after 6 months of TCZ treatment, which 
was also confirmed by immunofluorescence. Although confirmation of these results is required in 
further studies with larger sample sizes, these modifications may reflect a reduction of glomerular 
inflammation, and the amelioration of the podocyte integrity may further suggest a mitigation of 
tubular damage, as proposed by other authors48–51. Considering the endothelial microenvironment, 
the absence of significant downregulation in total ENDATs post-TCZ treatment may reflect the 
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In conclusion, treatment with TCZ as a first-line approach for cAMR shows early 
improvements in serological and histological findings with stable renal function, even in advanced 
TG. This may support the individual role of TCZ in cAMR without the need for rituximab-based 
first-line treatments with controversial evidence of effectiveness and potentially negative side 
effects and should encourage randomized controlled trials on IL-6/IL-6R blockade as a first-line 
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FIGURE LEGENDS
Figure 1: Renal function pre- and post–tocilizumab (TCZ) treatment. (A) Median estimated 
glomerular filtration rate (eGFR) values of TCZ-treated cAMR patients. eGFR was evaluated 3, 6 
and 12 months both before and after TCZ treatment (CKD-EPI equation), showing stabilization at 
the last follow-up (12 months) (eGFR -12 months vs t0, p = 0.002; eGFR t0 vs 12 months, p = 
0.006). (B) Median 24-hour proteinuria was unchanged at 6 and 12 months after TCZ treatment (p 
= 0.410 and 0.925, respectively).
Figure 2: Histological evaluation pre- and post–tocilizumab (TCZ) treatment. (A) Banff 
scores at diagnosis in patients with available pre- and post-TCZ allograft biopsies. Patients had 
significant microvascular inflammation (g and ptc) and severe transplant glomerulopathy (cg). (B, 
a-d) Changes in allograft biopsies before and after TCZ. Significant reduction in microvascular 
inflammation (g+ptc) (p = 0.019) was observed after TCZ treatment in 6-month protocol biopsies 
with no progression in chronicity scores (cg and IF/TA).
Figure 3: Immunodominant anti-HLA donor-specific antibody (iDSA) and anti-AT1R IgG 
values pre- and post-tocilizumab (TCZ) treatment. (A-B) iDSA mean fluorescence intensity 
(MFI) values in patients with available protocol biopsies. All iDSAs were of class 2. A significant 
reduction was observed after 6 months of therapy with TCZ (p = 0.002). (C) A significant 
reduction in the median concentration of anti-AT1R IgG was seen after TCZ treatment (p = 0.003).
Figure 4: Gene-expression analysis pre- and post–tocilizumab (TCZ) treatment. (A-B) 
Relative quantification (2-∆∆Ct) of the expression of ENDAT genes and three mesangial and 
podocyte marker genes in healthy controls (CTR) compared to patients before and after treatment 
with TCZ. The upper box and whiskers plots show the distribution of all values from minimum to 
maximum and the mean for the group of analyzed ENDAT genes. The bar graphs represent 
geometric mean ± 95% CI. (A) ENDATs were similarly upregulated pre and post TCZ. (B) TJP-1 
and AKR1C3 showed a non-significant downregulation in cAMR patients compared to controls 
and were significantly upregulated after TCZ. CASK was significantly downregulated before TCZ 
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dependent serine protein kinase; TJP-1: Tight junction protein 1; AKR1C3: Aldo-keto reductase 
family 1 member C3. *: p < 0.05; **: p < 0.01.
Figure 5: Immunofluorescence assay on kidney biopsies pre- and post–tocilizumab (TCZ) 
treatment. Pre- and post-treatment sections are stained for TJP-1 (green, A-B), AKR1C3 (C-D) or 
CASK (red, E-F). In the gene-expression analysis mean fluorescence intensity increased after 
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